aboutUs_006
聯絡我們English繁體中文簡體中文
logo_isdlogo_isd

Microbio

MENUMENU
MENUMENU
  • ABOUT US
    • ABOUT
    • CORE VALUE
    • COMPANY STRATEGY
    • ESTABLISHMENT HISTORY
    • CORPORATE LOGO
    • Management Team
    • GOVERNANCE STRUCTURE
  • R & D
    • new drug development
    • new drug development
      • MS-20
      • herbiron
      • ACADEMIC ARTICLE
    • MS-20 Zone
      • PRODUCT INFORMATION
      • RETAIL CHAIN
      • CLINICAL EFFICACY
      • FAQ
      • CONTACT US
    • Health Education Area
      • MS-20 (Health Education Area )
      • HERBIRON (HEALTH EDUCATION AREA )
  • SYMBIOTA™
  • MEDICAL DEVICES
  • NEWS
  • INVESTORS
    • Corporate Governance
      • GOVERNANCE STRUCTURE
      • CORPORATE GOVERNANCE OFFICER
      • BOARD OF DIRECTORS
      • MAJOR INTERNAL POLICIES
    • Financials
      • MONTHLY REVENUE
      • FINANCIAL REPORTS
    • INVESTOR CONFERENCE
      • INVESTOR CONFERENCE
    • SHAREHOLDERS’ MEETING
      • SHAREHOLDERS’ MEETING
  • ESG
    • SUSTAINABLE MANAGEMENT
      • Message from the Chairman
      • Sustainability Goals and Vision
      • Sustainability Performance
      • Sustainable Management Structure
      • Engagement with Stakeholders and Material Topics Analysis
      • Response to SDGs
    • social inclusion
      • Industry-Academia Collaboration
      • Public Welfare and Donation
      • Actions for Access to Medicines
      • Public participation
      • Supporting Animal Welfare Issues
    • HEALTH CARE
      • Innovative Drugs Research and Development
      • Clinical Trials
      • Drug Safety
      • Supply Chain Management
      • Health Product R&D and Safety
      • Food Quality and Safety
      • Customer Relationship Management
      • Ethical Marketing
    • CORPORATE GOVERNANCE
      • Governance Practices
      • Integrity-Based Operation
      • Internal Audit
      • Risk Management
      • Regulatory Compliance
      • Cyber Security
      • Intellectual Property Rights Protection
    • SAFE WORKPLACE
      • Trustworthy Employer
      • Talent Development and Cultivation
      • Compensation and Benefits
      • Labor Rights
      • Healthy and Safe Working Environment
    • ENVIRONMENTAL PROTECTION
      • Climate Actions
      • Usage of Water Resources
      • Waste Management
      • Environmental Management
      • Carbon Reduction Strategy
    • ESG DATABASE
      • ESG Report
      • Policy Statements and Management System Certificates
    • INTERACTION ZONE
      • STAKEHOLDER QUESTIONNAIRE
  • CAREERS
    • CHOOSE MICROBIO
    • COMPENSATION & BENEFITS
    • JOIN MICROBIO
    • LEARNING DEVELOPMENT
MENUMENU
MENUMENU
  • ABOUT US
    • ABOUT
    • CORE VALUE
    • COMPANY STRATEGY
    • ESTABLISHMENT HISTORY
    • CORPORATE LOGO
    • Management Team
    • GOVERNANCE STRUCTURE
  • R & D
    • new drug development
    • new drug development
      • MS-20
      • herbiron
      • ACADEMIC ARTICLE
    • MS-20 Zone
      • PRODUCT INFORMATION
      • RETAIL CHAIN
      • CLINICAL EFFICACY
      • FAQ
      • CONTACT US
    • Health Education Area
      • MS-20 (Health Education Area )
      • HERBIRON (HEALTH EDUCATION AREA )
  • SYMBIOTA™
  • MEDICAL DEVICES
  • NEWS
  • INVESTORS
    • Corporate Governance
      • GOVERNANCE STRUCTURE
      • CORPORATE GOVERNANCE OFFICER
      • BOARD OF DIRECTORS
      • MAJOR INTERNAL POLICIES
    • Financials
      • MONTHLY REVENUE
      • FINANCIAL REPORTS
    • INVESTOR CONFERENCE
      • INVESTOR CONFERENCE
    • SHAREHOLDERS’ MEETING
      • SHAREHOLDERS’ MEETING
  • ESG
    • SUSTAINABLE MANAGEMENT
      • Message from the Chairman
      • Sustainability Goals and Vision
      • Sustainability Performance
      • Sustainable Management Structure
      • Engagement with Stakeholders and Material Topics Analysis
      • Response to SDGs
    • social inclusion
      • Industry-Academia Collaboration
      • Public Welfare and Donation
      • Actions for Access to Medicines
      • Public participation
      • Supporting Animal Welfare Issues
    • HEALTH CARE
      • Innovative Drugs Research and Development
      • Clinical Trials
      • Drug Safety
      • Supply Chain Management
      • Health Product R&D and Safety
      • Food Quality and Safety
      • Customer Relationship Management
      • Ethical Marketing
    • CORPORATE GOVERNANCE
      • Governance Practices
      • Integrity-Based Operation
      • Internal Audit
      • Risk Management
      • Regulatory Compliance
      • Cyber Security
      • Intellectual Property Rights Protection
    • SAFE WORKPLACE
      • Trustworthy Employer
      • Talent Development and Cultivation
      • Compensation and Benefits
      • Labor Rights
      • Healthy and Safe Working Environment
    • ENVIRONMENTAL PROTECTION
      • Climate Actions
      • Usage of Water Resources
      • Waste Management
      • Environmental Management
      • Carbon Reduction Strategy
    • ESG DATABASE
      • ESG Report
      • Policy Statements and Management System Certificates
    • INTERACTION ZONE
      • STAKEHOLDER QUESTIONNAIRE
  • CAREERS
    • CHOOSE MICROBIO
    • COMPENSATION & BENEFITS
    • JOIN MICROBIO
    • LEARNING DEVELOPMENT

Aside

HomeArticles Posted by newsbuilder (Page 2)
news-3
News2025 年 3 月 4 日

NEWS

Announce on behalf of major subsidiary Cotton Field Organic Co.,Ltd. about its Board of Directors approved donations to related parties

54
Read More
news-3
News2025 年 3 月 4 日

NEWS

Announce on behalf of major subsidiary Cotton Field Organic Co.,Ltd. about its BOD resolution to convene the 2025 Annual Shareholders’meeting

56
Read More
news-3
News2025 年 2 月 27 日

NEWS

Microbio (Shanghai) confirmed the receiving of the second upfront payment, RMB 50 million, from CR Double Crane according to the agreement of Fespixon.

53
Read More
news-3
News2025 年 2 月 26 日

NEWS

Clarification regarding the media report on the exploratory clinical trial of MS20 combined with standard medications in UC meeting its primary endpoint

56
Read More
news-3
News2025 年 2 月 20 日

NEWS

Announcement for the expected date of the Board of Directors Meeting for 2024 Annual Financial Report is 2025/02/27

57
Read More
news-3
News2024 年 12 月 23 日

NEWS

Announces the information about the 2nd online investor’s conference of 2024.

36
Read More
news-3
News2024 年 12 月 11 日

NEWS

Microbio Honored with the Gold Award for Sustainability Report at the TCSA Taiwan Corporate Sustainability Awards

34
Read More
news-3
News2024 年 12 月 2 日

NEWS

Announcement on behalf of major subsidiary Cotton Field Organic Co.,Ltd. regarding acquisition of right-of-use asset for real estate from related party

39
Read More
news-3
News2024 年 12 月 2 日

NEWS

Announcement of the disposal of right-of-use asset for real estate to related party

36
Read More
news-3
News2024 年 11 月 12 日

NEWS

Announcement of Year 2024Q3 consolidated financial reports were approved by the BOD

30
Read More
1 2 3 4 … 21
Address: 14F-1, No. 3-1, Yuanqu St., Nangang Dist., Taipei City 115603, Taiwan (R.O.C.)
TEL: 02-2655-8558
FAX: 02-2655-8559
  • Facebook
  • YouTube
版權所有 © 中天生物科技股份有限公司. All Rights Reserved.
Copyright © Microbio Co., Ltd. All Rights Reserved.
隱私權條款 | 使用者條款
privacy policy | Terms of service

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.